Výsledky vyhledávání - "Alex Francisco Herrera"

Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial

Autor: Franck Morschhauser, Yanwen Jiang, Fabrice Jardin, Alex Francisco Herrera, Laurie Helen Sehn, Charles Herbaux, Christopher Flowers, Tycel Jovelle Phillips, Armando López Guillermo, Catherine S. Magid Diefenbach, Gareth Gregory, Austin Injae Kim, Anna Maria Barbui, Sandhya Balasubramanian, Will Harris, Jamie Hirata, Joseph N. Paulson, Calvin Lee, Georg Lenz

Publikováno v: Journal of Clinical Oncology. 40:7517-7517

7517 Background: Overexpression of BCL2 and MYC, and translocation of MYC, BCL2, and BCL6, are associated with poorer outcomes in patients (pts) with DLBCL (Horn et al. Blood 2013). We previously reported progression-free survival (PFS) from POLARIX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea8d63f5fe0379ae66e46e66ea7d3991
https://doi.org/10.1200/jco.2022.40.16_suppl.7517

Zobrazit plný text záznamu

Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma

Autor: Swetha Kambhampati, Monica Saumoy, Stacy Pak, L Elizabeth Budde, Matthew Genyeh Mei, Leslie Popplewell, Yi-Ping Wen, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alex Francisco Herrera, Nikhil Thiruvengadam

Publikováno v: Journal of Clinical Oncology. 40:7568-7568

7568 Background: In patients with treatment naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study demonstrated a 6.5% improvement in the 2-year (yr) progression-free survival (PFS) with no difference in overall survival or safety using polat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e49e3c681bc79e0c048fcd37ec3edd1c
https://doi.org/10.1200/jco.2022.40.16_suppl.7568

Zobrazit plný text záznamu

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

Autor: Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth Gregory, Alex Francisco Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Patricia Marinello, John Timmerman

Publikováno v: Journal of Clinical Oncology. 40:7516-7516

7516 Background: PD-1 inhibitors are a standard of care in pts with R/R cHL but new approaches are still needed to deepen and lengthen responses. Dual blockade of PD-1 and LAG-3 has demonstrated antitumor activity in preclinical models. The multicoho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b48e566edf5d1fe52a822fd3f8a6ee6b
https://doi.org/10.1200/jco.2022.40.16_suppl.7516

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání